CL2013000667A1 - Celulas de sangre total sin plasma; dispositivo para la utilización en un metodo de tratamiento de trasntornos del colesterol; sistema que comprende composicion que consiste en celulas de sangre total sin plasma y dispositivo; uso de plasmaféresis en dos o mas ciclos. - Google Patents
Celulas de sangre total sin plasma; dispositivo para la utilización en un metodo de tratamiento de trasntornos del colesterol; sistema que comprende composicion que consiste en celulas de sangre total sin plasma y dispositivo; uso de plasmaféresis en dos o mas ciclos.Info
- Publication number
- CL2013000667A1 CL2013000667A1 CL2013000667A CL2013000667A CL2013000667A1 CL 2013000667 A1 CL2013000667 A1 CL 2013000667A1 CL 2013000667 A CL2013000667 A CL 2013000667A CL 2013000667 A CL2013000667 A CL 2013000667A CL 2013000667 A1 CL2013000667 A1 CL 2013000667A1
- Authority
- CL
- Chile
- Prior art keywords
- plasma
- blood cells
- plasmapheresis
- cycles
- composition consisting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/12—Blood circulatory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Células de sangre total sin plasma; dispositivo para la utilización en un método de tratamiento de trastornos del colesterol; sistema que comprende composición que consiste en células de sangre total sin plasma y dispositivo; uso de plasmaféresis en dos o más ciclos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/418,123 US10624924B2 (en) | 2012-03-12 | 2012-03-12 | Method and device for treating blood cholesterol disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013000667A1 true CL2013000667A1 (es) | 2013-07-12 |
Family
ID=47891413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013000667A CL2013000667A1 (es) | 2012-03-12 | 2013-03-11 | Celulas de sangre total sin plasma; dispositivo para la utilización en un metodo de tratamiento de trasntornos del colesterol; sistema que comprende composicion que consiste en celulas de sangre total sin plasma y dispositivo; uso de plasmaféresis en dos o mas ciclos. |
Country Status (24)
Country | Link |
---|---|
US (1) | US10624924B2 (es) |
EP (1) | EP2638918B1 (es) |
JP (1) | JP6218401B2 (es) |
KR (2) | KR20130105452A (es) |
CN (2) | CN103301520A (es) |
AR (1) | AR090295A1 (es) |
AU (1) | AU2013201550B2 (es) |
BR (1) | BR102013005877B1 (es) |
CA (1) | CA2809012C (es) |
CL (1) | CL2013000667A1 (es) |
ES (1) | ES2598241T3 (es) |
HK (1) | HK1185791A1 (es) |
HU (1) | HUE029681T2 (es) |
IL (1) | IL225129A (es) |
MX (1) | MX344112B (es) |
MY (1) | MY169320A (es) |
NZ (1) | NZ608133A (es) |
PL (1) | PL2638918T3 (es) |
PT (1) | PT2638918T (es) |
RU (1) | RU2625774C2 (es) |
SG (1) | SG193729A1 (es) |
TW (1) | TWI554275B (es) |
UY (1) | UY34667A (es) |
ZA (1) | ZA201301815B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10624924B2 (en) | 2012-03-12 | 2020-04-21 | Grifols, S.A. | Method and device for treating blood cholesterol disorders |
AU2015201496B2 (en) * | 2014-06-03 | 2019-10-31 | Grifols Worldwide Operations Limited | Use of plasmapheresis to treat blood pressure disorders |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4374731A (en) | 1980-03-06 | 1983-02-22 | Baxter Travenol Laboratories, Inc. | Method and apparatus for obtaining a desired rate of plasma collection from a membrane plasmapheresis filter |
US4350156A (en) | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
US4540401A (en) * | 1983-02-22 | 1985-09-10 | Applied Immune Sciences, Inc. | In vivo therapeutic apheresis using lipid vesicles |
JPH0657250B2 (ja) | 1984-06-29 | 1994-08-03 | バクスター・インターナショナル・インコーポレーテッド | 血液抽出及び再注輸の血流制御装置 |
US5258149A (en) | 1990-11-27 | 1993-11-02 | W. R. Grace & Co.-Conn. | Process of making a membrane for high efficiency removal of low density lipoprotein-cholesterol from whole blood |
CA2095424A1 (en) | 1992-05-14 | 1993-11-15 | Marc Ellous Parham | Microporous polysulfone support suitable for removal of low density lipoprotein-cholesterol |
JPH06254152A (ja) * | 1993-03-03 | 1994-09-13 | Terumo Corp | 血漿交換装置 |
JPH0788179A (ja) * | 1993-09-22 | 1995-04-04 | Terumo Corp | 血漿交換装置 |
RU2113240C1 (ru) | 1995-05-05 | 1998-06-20 | Акционерное общество закрытого типа "Оптика" | Способ мембранного плазмафереза по одноигольной схеме под действием силы тяжести и устройство для его осуществления |
CA2220007A1 (en) | 1995-05-26 | 1996-11-28 | Diacrin, Inc. | Porcine hepatocytes for use in treatment of disorders characterized by insufficient liver function |
EP0874683A1 (en) | 1995-10-23 | 1998-11-04 | Hemasure, Inc. | Extra-lumenal crossflow plasmapheresis devices |
FR2747591B1 (fr) | 1996-04-19 | 1998-05-22 | Hospal Ind | Appareil medical pour le traitement extracorporel du sang ou du plasma et procedes de fabrication de cet appareil |
US5919902A (en) * | 1996-06-07 | 1999-07-06 | Eli Lilly And Company | Leptin bound to inter-alphatrypsin inhibitor and uses thereof |
US6627151B1 (en) | 1997-06-13 | 2003-09-30 | Helmut Borberg | Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion |
RU2153168C2 (ru) * | 1997-11-25 | 2000-07-20 | Научно-исследовательский институт кардиологии | Способ определения показаний к проведению плазмафереза при лечении стенокардии |
DE19821534C1 (de) | 1998-05-14 | 1999-08-19 | Braun Melsungen Ag | Blutreinigungsmaschine |
WO2000038760A2 (en) * | 1998-12-29 | 2000-07-06 | Occulogix Corporation | Rheological treatment methods and related apheresis systems |
DE60042088D1 (de) | 1999-04-30 | 2009-06-04 | Childrens Hosp Medical Center | Hämofiltrationssystem |
RU2195321C2 (ru) | 2000-11-16 | 2002-12-27 | Государственный научно-клинический центр охраны здоровья шахтеров | Способ лечения церебрального атеросклероза |
US6991727B2 (en) | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
US7854718B2 (en) | 2001-11-16 | 2010-12-21 | Fresenius Medical Care Holdings, Inc. | Dual-ventricle pump cartridge, pump and method of use in a wearable continuous renal replacement therapy device |
US6982038B2 (en) * | 2002-06-14 | 2006-01-03 | Medtronic, Inc. | Centrifuge system utilizing disposable components and automated processing of blood to collect platelet rich plasma |
WO2004000387A2 (en) | 2002-06-19 | 2003-12-31 | The Board Of Regents Of The University Of Texas System | Dialysis system for treatment of vulnerable patients and methods of use |
AU2003303198A1 (en) | 2002-12-19 | 2004-07-14 | New York University | Method for treating amyloid disease |
US7393826B2 (en) | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
WO2005011620A2 (en) * | 2003-07-03 | 2005-02-10 | Lipid Sciences Inc. | Methods and apparatus for creating particle derivatives of hdl with reduced lipid content |
US20100316730A1 (en) * | 2003-07-31 | 2010-12-16 | Latino Joseph S | Treatment of cardiovascular diseases with ozone |
WO2005018715A1 (en) | 2003-07-31 | 2005-03-03 | Lipidviro Tech | Ozone delivery system including gas-fluid contacting devices and methods of use |
US8038638B2 (en) | 2004-02-23 | 2011-10-18 | Hemolife Medical, Inc. | Plasma detoxification and volume control system and methods of use |
DE102004054747A1 (de) | 2004-11-12 | 2006-05-24 | Fresenius Medical Care Deutschland Gmbh | Verfahren und Vorrichtung zur Abreicherung wenigstens einer Komponente eines fluiden Mediums |
RU2310478C1 (ru) | 2006-05-03 | 2007-11-20 | Александр Георгиевич Рожков | Способ лечения атеросклероза |
GB0621452D0 (en) | 2006-10-27 | 2006-12-06 | Ucl Business Plc | Therapy for liver disease |
CN100500229C (zh) | 2006-12-29 | 2009-06-17 | 上海达华医疗器械有限公司 | 一种多功能体外血液治疗仪 |
FR2911417B1 (fr) | 2007-01-17 | 2009-02-27 | Gambro Lundia Ab | Suivi de l'acces vasculaire d'un patient soumis a des seances successives de traitement extracorporel de sang |
US20120165685A1 (en) | 2010-12-22 | 2012-06-28 | Weasler Marc N | Plasmapheresis donor display and method of use |
CN201006071Y (zh) | 2007-02-13 | 2008-01-16 | 沈建华 | 一种智能输液泵 |
US8409441B2 (en) | 2007-02-27 | 2013-04-02 | Deka Products Limited Partnership | Blood treatment systems and methods |
MX2011006545A (es) | 2008-12-19 | 2011-11-01 | Anthera Pharmaceuticals Inc | Tratamiento de eventos cardiacos adversos principales y sindrome coronario agudo usando inhibidor de fosfolipasa secretora a2 (spla2) o terapias de combinacion con el inhibidor spla2. |
WO2011015380A1 (en) | 2009-08-05 | 2011-02-10 | Celltrend Gmbh | Method for prognosis of pulmonary arterial hypertension by detecting anti-par2-antibodies |
EP2485983B1 (en) | 2009-10-08 | 2017-05-03 | Otsuka Pharmaceutical Co., Ltd. | An immunoactivation blood perfusion filter for the treatment of malignant tumors |
WO2011080191A1 (en) | 2009-12-28 | 2011-07-07 | Gambro Lundia Ab | Monitoring blood pressure |
US10052345B2 (en) | 2010-10-19 | 2018-08-21 | University Of Miami | Assays, methods and kits for predicting renal disease and personalized treatment strategies |
CA2826563C (en) | 2011-02-07 | 2020-10-20 | Paul Kussie | Methods and systems for treating eclampsia and pre-eclampsia |
US10624924B2 (en) | 2012-03-12 | 2020-04-21 | Grifols, S.A. | Method and device for treating blood cholesterol disorders |
-
2012
- 2012-03-12 US US13/418,123 patent/US10624924B2/en active Active
-
2013
- 2013-03-05 ES ES13157889.0T patent/ES2598241T3/es active Active
- 2013-03-05 HU HUE13157889A patent/HUE029681T2/en unknown
- 2013-03-05 EP EP13157889.0A patent/EP2638918B1/en active Active
- 2013-03-05 PT PT131578890T patent/PT2638918T/pt unknown
- 2013-03-05 PL PL13157889T patent/PL2638918T3/pl unknown
- 2013-03-07 ZA ZA2013/01815A patent/ZA201301815B/en unknown
- 2013-03-07 CA CA2809012A patent/CA2809012C/en active Active
- 2013-03-08 MX MX2013002681A patent/MX344112B/es active IP Right Grant
- 2013-03-08 TW TW102108168A patent/TWI554275B/zh active
- 2013-03-08 MY MYPI2013700376A patent/MY169320A/en unknown
- 2013-03-10 IL IL225129A patent/IL225129A/en active IP Right Grant
- 2013-03-11 UY UY0001034667A patent/UY34667A/es not_active Application Discontinuation
- 2013-03-11 RU RU2013110503A patent/RU2625774C2/ru active
- 2013-03-11 AR ARP130100773A patent/AR090295A1/es not_active Application Discontinuation
- 2013-03-11 AU AU2013201550A patent/AU2013201550B2/en active Active
- 2013-03-11 CL CL2013000667A patent/CL2013000667A1/es unknown
- 2013-03-12 NZ NZ608133A patent/NZ608133A/en unknown
- 2013-03-12 CN CN2013100785746A patent/CN103301520A/zh active Pending
- 2013-03-12 KR KR1020130026154A patent/KR20130105452A/ko active Application Filing
- 2013-03-12 BR BR102013005877-7A patent/BR102013005877B1/pt active IP Right Grant
- 2013-03-12 CN CN201711120194.9A patent/CN107754038A/zh active Pending
- 2013-03-12 SG SG2013018247A patent/SG193729A1/en unknown
- 2013-03-12 JP JP2013048810A patent/JP6218401B2/ja active Active
- 2013-11-25 HK HK13113090.7A patent/HK1185791A1/zh unknown
-
2018
- 2018-06-25 KR KR1020180072810A patent/KR101908899B1/ko active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
BR112016008694A2 (pt) | Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit | |
BR112017019738A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
BR112014026990A2 (pt) | anticorpo , ácido nucleico , vetores , célula hospedeira , composição farmacêutica , uso de um anticorpo e método para o tratamento de um paciente com necessidade de terapia. | |
CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
CL2015000092A1 (es) | Oligonucleótidos quiralmente controlados, composición que los comprende; método de elaboración: y uso para tratar cáncer. | |
CL2016001076A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. | |
BR112017005598A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
BR112015032392A2 (pt) | sistemas e métodos de entrega de terapia usando um dispositivo médico ambulatorial | |
PT2848097T (pt) | Dispositivo para o tratamento de plasma de superfícies humanas, animais ou de plantas, em particular da pele ou de áreas de membrana mucosa | |
DK3311827T3 (da) | Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser | |
BR112014000796A2 (pt) | localizadores esternais e sistemas e métodos associados | |
BR112015023203A8 (pt) | métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer. | |
BR112013031210A2 (pt) | processo para o tratamento das fibras queratínicas, kit e uso de um dispositivo | |
DK2815769T3 (da) | Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet | |
AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
BR112017004059A2 (pt) | dispositivo de hemoperfusão utilizável | |
BR112015023439A2 (pt) | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki | |
BR112015027477A8 (pt) | bolus, seus usos, e kit | |
BR112015004260A2 (pt) | dispositivo e processo para o tratamento de tecido biológico mediante o uso de um plasma de baixa pressão | |
CY1118968T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. | |
FR2997019B1 (fr) | Dispositif, appareil et procede de traitement cosmetique par la lumiere | |
BRPI0922117A2 (pt) | aparelho para uso em tratamento terapêutico e/ou cosmético, método para realizar um tratamento terapêutico e/ou cosmético, uso de um aparelho, e, aparelho. | |
EA201691108A1 (ru) | Хиназолин-thf-амины в качестве ингибиторов pde1 |